Compare TWST & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | WVE |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2018 | 2015 |
| Metric | TWST | WVE |
|---|---|---|
| Price | $44.88 | $12.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $48.75 | $31.47 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 05-04-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $376,572,000.00 | $3,704,000.00 |
| Revenue This Year | $18.89 | N/A |
| Revenue Next Year | $15.28 | $119.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 20.32 | ★ 149.43 |
| 52 Week Low | $23.30 | $5.28 |
| 52 Week High | $57.88 | $21.73 |
| Indicator | TWST | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 42.11 |
| Support Level | $42.89 | $12.53 |
| Resistance Level | $45.76 | $15.02 |
| Average True Range (ATR) | 2.59 | 0.82 |
| MACD | -0.79 | -0.08 |
| Stochastic Oscillator | 29.27 | 6.46 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.